AGN-191659 is an orally active RAR/RXR agonist with EC 50 values of 11 nM, 23 nM, and 37 nM for RXRα , RARβ , and RARγ , respectively. AGN-191659 activates RXRα , RARβ and RARγ to induce gene transcription. AGN-191659 induces tissue transglutaminase activity, inhibits ornithine decarboxylase activity induced by tumor promoters, and suppresses chondrogenesis. AGN-191659 reverses basic fibroblast growth factor-induced endothelial cell proliferation. AGN-191659 induces hypertriglyceridemia in rat models. AGN-191659 inhibits total heparin-releasable lipase activity. AGN-191659 can be used in research related to promyelocytic leukemia and hypertriglyceridemia.
Products | Products > Disease Areas > Blood Disease | Products > Disease Areas > Hypertriglyceridemia | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > RAR/RXR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.